This page is an archive. Its content may no longer be accurate and was last updated on the original publication date. It is intended for reference and as a historical record only. For hep C questions, call Help4Hep BC at 1-888-411-7578.
For patients infected with hepatitis C virus(HCV) without advanced liver disease, achieving sustained virologic response with direct-acting antivirals (DAAs) is associated with decreased mortality, according to results published in Hepatology.
The mortality rate of patients who achieved sustained virologic response was 1.18 deaths/100 patient years compared with 2.84 deaths/100 patient years for patients who did not achieve sustained virologic response, and 3.84 deaths/100 patient years for untreated patients.
“Increasing access to DAAs for all HCV-infected individuals should result in fewer deaths,” the researchers wrote.